Cargando…
Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
Soft tissue sarcomas (STS) are heterogeneous mesenchymal tumors with limited therapeutic options in the advanced setting. Immune checkpoint inhibitors have been shown to have significant clinical activity in inflamed STS which are characterized by the presence of tertiary lymphoid structures (TLS)....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609223/ https://www.ncbi.nlm.nih.gov/pubmed/36303228 http://dx.doi.org/10.1186/s13045-022-01377-2 |
_version_ | 1784818966180397056 |
---|---|
author | Spalato-Ceruso, Mariella Bouteiller, Fanny Guegan, Jean-Philippe Toulmonde, Maud Bessede, Alban Kind, Michèle Cousin, Sophie Buy, Xavier Palussiere, Jean Le Loarer, François Dadone-Montaudie, Berengere Pulido, Marina Italiano, Antoine |
author_facet | Spalato-Ceruso, Mariella Bouteiller, Fanny Guegan, Jean-Philippe Toulmonde, Maud Bessede, Alban Kind, Michèle Cousin, Sophie Buy, Xavier Palussiere, Jean Le Loarer, François Dadone-Montaudie, Berengere Pulido, Marina Italiano, Antoine |
author_sort | Spalato-Ceruso, Mariella |
collection | PubMed |
description | Soft tissue sarcomas (STS) are heterogeneous mesenchymal tumors with limited therapeutic options in the advanced setting. Immune checkpoint inhibitors have been shown to have significant clinical activity in inflamed STS which are characterized by the presence of tertiary lymphoid structures (TLS). New strategies are needed to sensitize TLS-negative STS to immunotherapy. Engagement of the toll-Like Receptor 4 (TLR4) signal pathway contributes to the development of a favorable tumor microenvironment in solid tumors. G100 is a highly potent toll-like receptor 4 (TLR4) agonist. We hypothesized that intra-tumoral G100 would induce a robust local and potentially systemic anti-tumor immune response in the microenvironment of TLS-negative sarcoma, leading to improved response to PD1 inhibition. Twenty metastatic STS patients who had a superficial injectable lesion were treated with 50 mg of cyclophosphamide (CP) orally twice daily (1 week on and 1 week off), 200 mg of pembrolizumab intravenously on day 8 of a planned 21-day cycle and G100 20 µg one weekly intra-tumoral injection for at least 6 weeks and for a maximum of 12 weeks (1st injection one week before CP administration, ie. Day -7). Biopsies and blood were collected pre and post treatment. Of the 17 patients assessable for efficacy analysis, 2 were progression-free at 6 months, and the 6-month non-progression rate was 11.8% (95% CI: 1.5–36.4), indicating that the first endpoint of the study was not reached. In 8 patients, there was an increase in T-cell infiltration into tumor after treatment. The ratio CD8/Fox-P3 + CD4 on treatment decreased in 11 cases out of 14 suggesting a predominant induction of Treg. Soluble PDL1 levels at baseline were also with adverse outcome. G100 appears to modulate the tumor microenvironment with significant infiltration of T cells. However, clinical activity in combination with PD1 inhibition was limited and no clear correlation was observed between tumor shrinkage and increased inflammation. TLR4 stimulation might have both antitumor and pro-tumor consequences. Trial registration: This study was registered with ClinicalTrial.gov, number NCT02406781. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01377-2. |
format | Online Article Text |
id | pubmed-9609223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96092232022-10-28 Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study Spalato-Ceruso, Mariella Bouteiller, Fanny Guegan, Jean-Philippe Toulmonde, Maud Bessede, Alban Kind, Michèle Cousin, Sophie Buy, Xavier Palussiere, Jean Le Loarer, François Dadone-Montaudie, Berengere Pulido, Marina Italiano, Antoine J Hematol Oncol Correspondence Soft tissue sarcomas (STS) are heterogeneous mesenchymal tumors with limited therapeutic options in the advanced setting. Immune checkpoint inhibitors have been shown to have significant clinical activity in inflamed STS which are characterized by the presence of tertiary lymphoid structures (TLS). New strategies are needed to sensitize TLS-negative STS to immunotherapy. Engagement of the toll-Like Receptor 4 (TLR4) signal pathway contributes to the development of a favorable tumor microenvironment in solid tumors. G100 is a highly potent toll-like receptor 4 (TLR4) agonist. We hypothesized that intra-tumoral G100 would induce a robust local and potentially systemic anti-tumor immune response in the microenvironment of TLS-negative sarcoma, leading to improved response to PD1 inhibition. Twenty metastatic STS patients who had a superficial injectable lesion were treated with 50 mg of cyclophosphamide (CP) orally twice daily (1 week on and 1 week off), 200 mg of pembrolizumab intravenously on day 8 of a planned 21-day cycle and G100 20 µg one weekly intra-tumoral injection for at least 6 weeks and for a maximum of 12 weeks (1st injection one week before CP administration, ie. Day -7). Biopsies and blood were collected pre and post treatment. Of the 17 patients assessable for efficacy analysis, 2 were progression-free at 6 months, and the 6-month non-progression rate was 11.8% (95% CI: 1.5–36.4), indicating that the first endpoint of the study was not reached. In 8 patients, there was an increase in T-cell infiltration into tumor after treatment. The ratio CD8/Fox-P3 + CD4 on treatment decreased in 11 cases out of 14 suggesting a predominant induction of Treg. Soluble PDL1 levels at baseline were also with adverse outcome. G100 appears to modulate the tumor microenvironment with significant infiltration of T cells. However, clinical activity in combination with PD1 inhibition was limited and no clear correlation was observed between tumor shrinkage and increased inflammation. TLR4 stimulation might have both antitumor and pro-tumor consequences. Trial registration: This study was registered with ClinicalTrial.gov, number NCT02406781. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01377-2. BioMed Central 2022-10-27 /pmc/articles/PMC9609223/ /pubmed/36303228 http://dx.doi.org/10.1186/s13045-022-01377-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Correspondence Spalato-Ceruso, Mariella Bouteiller, Fanny Guegan, Jean-Philippe Toulmonde, Maud Bessede, Alban Kind, Michèle Cousin, Sophie Buy, Xavier Palussiere, Jean Le Loarer, François Dadone-Montaudie, Berengere Pulido, Marina Italiano, Antoine Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study |
title | Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study |
title_full | Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study |
title_fullStr | Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study |
title_full_unstemmed | Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study |
title_short | Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study |
title_sort | pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist g100 in patients with advanced pretreated soft tissue sarcoma: results from the pembrosarc basket study |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609223/ https://www.ncbi.nlm.nih.gov/pubmed/36303228 http://dx.doi.org/10.1186/s13045-022-01377-2 |
work_keys_str_mv | AT spalatocerusomariella pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT bouteillerfanny pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT gueganjeanphilippe pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT toulmondemaud pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT bessedealban pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT kindmichele pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT cousinsophie pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT buyxavier pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT palussierejean pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT leloarerfrancois pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT dadonemontaudieberengere pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT pulidomarina pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy AT italianoantoine pembrolizumabcombinedwithlowdosecyclophosphamideandintratumoralinjectionofthetolllikereceptor4agonistg100inpatientswithadvancedpretreatedsofttissuesarcomaresultsfromthepembrosarcbasketstudy |